贝林妥欧单抗作为儿童B细胞急性淋巴细胞白血病合并侵袭性真菌病的桥接治疗
侵袭性真菌病(IFD)是儿童急性白血病治疗的棘手并发症,共识指南建议暂停化疗以促进免疫恢复,但延迟白血病治疗增加复发风险。贝林妥欧单抗靶向CD19的双特异性T细胞衔接器,在复发/难治性B-ALL中显示疗效且毒性低于常规化疗。通过密切监测微小残留病,本研究表明儿童B-ALL可在暂停常规化疗、等待IFD治疗和恢复期间接受重复周期的桥接贝林妥欧单抗治疗。
要点
- 共识真菌治疗指南建议暂停化疗以促进免疫恢复。
- 贝林妥欧单抗在复发/难治性B-ALL中显示疗效且毒性低于常规化疗。
- 密切监测微小残留病下,患儿可接受重复周期桥接贝林妥欧单抗。
核心结论
- 儿童B-ALL合并IFD时,在暂停常规化疗期间可接受重复周期的桥接贝林妥欧单抗治疗,并密切监测微小残留病。
研究设计与样本
- 原文未报告研究设计与样本量。
主要发现
- 儿童B-ALL患者可在常规化疗暂停、IFD治疗和恢复期间接受重复周期的桥接贝林妥欧单抗治疗。
- 贝林妥欧单抗靶向表达CD19的细胞,在复发/难治性B-ALL中显示疗效且毒性低于常规化疗。
关键数值与推荐
- 共识真菌治疗指南推荐暂停化疗以促进免疫恢复。
- 贝林妥欧单抗是靶向CD19的双特异性T细胞衔接器。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Invasive fungal disease (IFD) remains a challenging complication of treatment for paediatric acute leukaemia. Consensus fungal treatment guidelines recommend withholding chemotherapy to facilitate immune recovery in this setting, yet prolonged delays in leukaemia therapy increase risk of relapse. Blinatumomab, a bispecific T-cell engager targeting cells expressing CD19, has shown promise for treatment of relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) and is associated with reduced toxicity compared to conventional chemotherapy. With close monitoring of minimal residual disease, we demonstrate that children with B-ALL can receive repeated cycles of bridging blinatumomab whilst conventional chemotherapy is withheld during treatment and recovery from IFD.
引用
- Yeoh DK, Blyth CC, Kotecha RS, et al. Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease. Br J Haematol. 2022. PMID: 35727917. doi:10.1111/bjh.18314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。